Compare Nasdaq Inc (NDAQ) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nasdaq Inc vs Stryker Corporation — how do they compare? Nasdaq Inc trades at $93.6 (market cap $51.63B), while Stryker Corporation trades at $277.3 (market cap $106.24B). The key difference: Stryker Corporation is far larger — about 2.1× Nasdaq Inc's market cap, and Stryker Corporation pays the higher dividend (1.27%). Which is the better fit depends on your goals — on Pluang, investors hold Nasdaq Inc for 126 Days and Stryker Corporation for 21 Days on average.
| NDAQ | SYK | |
|---|---|---|
Market Cap | $51.63B | $106.24B |
Volume | 2,668,175 | 2,982,001 |
Sector | Financials | Health |
52-Week High | $100.98 | $388.35 |
52-Week Low | $76.85 | $269.75 |
Typical Hold Time | 126 Days | 21 Days |
Enterprise Value | $58.09B | $117.70B |
Dividend Yield | 1.26% | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nasdaq (NDAQ) trades at $93.51, up 1.72% today, with a bullish technical signal and strong earnings beats in recent quarters. Revenue grew to $8.26B in 2025, with net income margin expanding to 22.52%. Analyst consensus is a Buy with a $110.43 price target, supported by positive news on AI platform adoption and index changes.
Outlook remains positive given earnings momentum and Financial Technology growth, though risks include market volatility and debt levels. The stock offers upside to consensus targets but faces execution risks in tech integration and competitive pressures.
Stryker (SYK) trades at $277.52, up 0.77% today, amid a mixed technical and fundamental backdrop. The stock shows a bearish technical signal with key support at $274 and resistance at $279. Fundamentally, the company reported strong profitability with a 14.43% net income margin in 2026 and beat EPS estimates in two of the last three quarters. However, recent news highlights potential legal and manufacturing issues that have pressured investor sentiment.
The outlook is cautiously optimistic, with a consensus price target of $368.11 implying significant upside. Investment opportunities lie in SYK's robust earnings growth and market leadership in medical technology, but risks include ongoing legal investigations and persistent manufacturing challenges that could impact future performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nasdaq Inc
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
Read more on NDAQ →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
